date,title,source
Oct-23-18,Oramed to Present at Cardiometabolic Health Congress,PR Newswire
Nov-05-18,Oramed to Present at the Tides Europe 2018 Conference,PR Newswire
Nov-13-18,Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study,PR Newswire
Nov-15-18,ORMP: Transferring Coverage; Multiple Clinical Readouts for Oral Protein Delivery Technology Over Next 12-18 Months,Zacks Small Cap Research
Nov-27-18,Is Oramed Pharmaceuticals Incs (NASDAQ:ORMP) CEO Paid Enough Relative To Peers?,Simply Wall St.
Dec-17-18,ORMP: Two Studies Ongoing for ORMD-0801 with Data Readouts in 2019,Zacks Small Cap Research
Jan-09-19,Oramed Receives Additional $3 Million Milestone Payment from HTIT,PR Newswire
Jan-15-19,Oramed Pharmaceuticals' CEO Letter to Shareholders,PR Newswire
Jan-22-19,Oramed Initiates Phase I Oral GLP-1 Study Under IND,PR Newswire
Jan-24-19,ORMP: Multiple Catalysts in 2019,Zacks Small Cap Research
Feb-06-19,Does The Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Share Price Tend To Follow The Market?,Simply Wall St.
Feb-06-19,Oramed to Present at BIO CEO & Investor Conference,PR Newswire
Mar-26-19,Chinese Regulatory Authority  Approves IND Application of Oramed's Oral Insulin Capsules,PR Newswire
Mar-28-19,Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology,PR Newswire
Apr-03-19,Oramed to Present at H.C. Wainwright Global Life Sciences Conference,PR Newswire
Apr-04-19,Oramed Patent Allowed in the U.S. for Oral Exenatide,PR Newswire
Apr-11-19,Oramed to Present at 3rd Annual Clinical Trials Summit,PR Newswire
Apr-29-19,Oramed to Present at ThinkEquity Conference,PR Newswire
May-07-19,ORMP: Data from Phase 1 Trial of Oral GLP-1 in 2Q19,Zacks Small Cap Research
